Home » General World News » Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we treat genetic diseases

Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we treat genetic diseases





Novartis CEO Vas Narasimhan

  • Novartis is acquiring gene therapy company AveXis for $8.7 billion.
  • AveXis is working on a gene therapy for spinal muscular atrophy, a rare genetic condition that affects muscle movement in children and is the leading genetic cause of mortality in infants.
  • It’s part of a wave of big bets in gene therapy, a cutting-edge area of science that has had some big advancements over the past year.

Novartis said on Monday that it’s acquiring rare disease drugmaker AveXis for $8.7 billion.

AveXis is working on a treatment for spinal muscular atrophy (SMA), a rare genetic condition that affects muscle movement. It’s the read more >>>

Source:: BusinessInsider.Com

Comments are closed.